EW Edwards Lifesciences Corp

Price (delayed)

$89.14

Market cap

$53.66B

P/E Ratio

38.26

Dividend/share

N/A

EPS

$2.33

Enterprise value

$53.14B

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of ...

Highlights
EW's quick ratio is up by 23% year-on-year and by 12% since the previous quarter
The equity has grown by 19% year-on-year and by 7% since the previous quarter
The price to earnings (P/E) is 17% lower than the 5-year quarterly average of 46.2 but 5% higher than the last 4 quarters average of 36.3
The net income has contracted by 5% YoY
EW's gross margin is down by 4% year-on-year

Key stats

What are the main financial stats of EW
Market
Shares outstanding
602M
Market cap
$53.66B
Enterprise value
$53.14B
Valuations
Price to book (P/B)
7.53
Price to sales (P/S)
8.73
EV/EBIT
32.59
EV/EBITDA
29.39
EV/Sales
8.65
Earnings
Revenue
$6.14B
EBIT
$1.63B
EBITDA
$1.81B
Free cash flow
$271.4M
Per share
EPS
$2.33
Free cash flow per share
$0.45
Book value per share
$11.84
Revenue per share
$10.21
TBVPS
$13.36
Balance sheet
Total assets
$9.74B
Total liabilities
$2.55B
Debt
$699.2M
Equity
$7.12B
Working capital
$3.06B
Liquidity
Debt to equity
0.1
Current ratio
3.75
Quick ratio
2.32
Net debt/EBITDA
-0.29
Margins
EBITDA margin
29.4%
Gross margin
76.6%
Net margin
23%
Operating margin
24.5%
Efficiency
Return on assets
15.1%
Return on equity
21.1%
Return on invested capital
27.3%
Return on capital employed
18.9%
Return on sales
26.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EW stock price

How has the Edwards Lifesciences stock price performed over time
Intraday
-1.08%
1 week
2.79%
1 month
2.18%
1 year
1.69%
YTD
16.9%
QTD
-6.72%

Financial performance

How have Edwards Lifesciences's revenue and profit performed over time
Revenue
$6.14B
Gross profit
$4.71B
Operating income
$1.51B
Net income
$1.41B
Gross margin
76.6%
Net margin
23%
The company's operating margin fell by 19% YoY and by 2.4% QoQ
The net margin has contracted by 15% YoY
EW's revenue is up by 12% year-on-year and by 2.3% since the previous quarter
The operating income has contracted by 10% YoY

Growth

What is Edwards Lifesciences's growth rate over time

Valuation

What is Edwards Lifesciences stock price valuation
P/E
38.26
P/B
7.53
P/S
8.73
EV/EBIT
32.59
EV/EBITDA
29.39
EV/Sales
8.65
The price to earnings (P/E) is 17% lower than the 5-year quarterly average of 46.2 but 5% higher than the last 4 quarters average of 36.3
The company's EPS fell by 3.3% YoY
The stock's price to book (P/B) is 28% less than its 5-year quarterly average of 10.4
The equity has grown by 19% year-on-year and by 7% since the previous quarter
The P/S is 19% below the 5-year quarterly average of 10.8
EW's revenue is up by 12% year-on-year and by 2.3% since the previous quarter

Efficiency

How efficient is Edwards Lifesciences business performance
The company's return on sales fell by 17% YoY
Edwards Lifesciences's return on equity has decreased by 15% YoY and by 3.7% QoQ
EW's return on assets is down by 14% year-on-year
The company's return on invested capital fell by 12% YoY and by 2.5% QoQ

Dividends

What is EW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EW.

Financial health

How did Edwards Lifesciences financials performed over time
The company's current ratio rose by 25% YoY and by 11% QoQ
EW's quick ratio is up by 23% year-on-year and by 12% since the previous quarter
The debt is 90% less than the equity
The equity has grown by 19% year-on-year and by 7% since the previous quarter
The company's debt to equity fell by 17% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.